160 related articles for article (PubMed ID: 38478154)
1. Flare phenomenon visualized by
Zhang X; Nakajima K; Mizokami A; Horikoshi H; Nishimoto K; Hashine K; Matsuyama H; Takahashi S; Wakabayashi H; Kinuya S
Ann Nucl Med; 2024 Jun; 38(6):428-440. PubMed ID: 38478154
[TBL] [Abstract][Full Text] [Related]
2. Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy.
Kadomoto S; Yaegashi H; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Nakajima K; Mizokami A
Anticancer Res; 2019 May; 39(5):2553-2559. PubMed ID: 31092452
[TBL] [Abstract][Full Text] [Related]
3. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
[TBL] [Abstract][Full Text] [Related]
4. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
Higashiyama S; Yoshida A; Kawabe J
Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
[TBL] [Abstract][Full Text] [Related]
5. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
[TBL] [Abstract][Full Text] [Related]
7. Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases.
Hirano H; Nagata M; Nagaya N; Nakamura S; Ashizawa T; Lu Y; Kawano H; Kitamura K; Sakamoto Y; Fujita K; Isobe H; Tsujimura A; Muto S; Horie S
Sci Rep; 2023 May; 13(1):8704. PubMed ID: 37248346
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
[TBL] [Abstract][Full Text] [Related]
10. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Han KS; Hong SJ
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
12. [Role of Bone Scan Index (BSI) in the Prognosis and Treatment Efficacy in Castration-Sensitive Prostate Cancer Patients with Bone Metastasis].
Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
14. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
15. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
[TBL] [Abstract][Full Text] [Related]
16.
Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
[TBL] [Abstract][Full Text] [Related]
17. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
Anand A; Morris MJ; Larson SM; Minarik D; Josefsson A; Helgstrand JT; Oturai PS; Edenbrandt L; Røder MA; Bjartell A
EJNMMI Res; 2016 Dec; 6(1):23. PubMed ID: 26960325
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
19. The CT flare response of metastatic bone disease in prostate cancer.
Messiou C; Cook G; Reid AH; Attard G; Dearnaley D; de Bono JS; de Souza NM
Acta Radiol; 2011 Jun; 52(5):557-61. PubMed ID: 21498309
[TBL] [Abstract][Full Text] [Related]
20. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
